Apr 17, 2026
Datopotamab Deruxtecan Nearly Doubles Survival in Triple-Negative Breast Cancer Trial
Global phase III TROPION-Breast02 trial led by National Cancer Centre Singapore shows datopotamab deruxtecan significantly improves survival outcomes in triple-negative breast cancer patients, representing a major breakthrough for this aggressive cancer type.
1 source
00